Figure. A: Neopla stic L ymphoi d folli cles are packed closely together: They lack a mantle zone, and they have no central germinal center. B: Follicular lymphoma extends beyond the lymph node capsule and into extran odal adipose tissue.
B Follicular lymphoma is defined as a neoplasm of follicle center B lymphocytes (centrocytes and centroblasts) that has at least a partially follicular growth pattern . It is a lowgrade lymphoma, and its course is indolent. Most patients present during the sixth decade of life ; the neoplasm is very rare in patients younger than 20 years of age. The female-to-male ratio is 1.7:1. Lymph node enlargement is the usual presentation; only about 20 % of patients have B symptoms (i.e., fever, chills, night sweats, and weight loss). The disease is usually systemic at presentation (stage III or IV). In the head and neck region , follicular lymphoma may involve lymph nodes, Waldeyer's ring, and/or skin.
Histologically, the characteristic finding is the presence of uniform neoplastic lymphoid follicles packed closely together ( figure, A) , usually effacing the nodal architecture and often extending out into the extranodal fat (figure, B). Neopl astic follicles are poorly defined; they lack a mantle zone and polarization; they have few mitotic figures; and they tend to lack tingible-body macrophages. The neoplastic cells vary from small to large, showing folding and cleaving of the nucle i, resembling centrocytes (small-to medium-sized cleaved cells with inconspicuous nucleoli) and centroblasts (large noncleaved cells with vesicular chromatin and several peripheral nucleoli).
There are several histologic variants of follicular lymphoma: signet ring cell type, plasmacytoid type, marginal zone type, floral variant with amorphous extracellular material, and diffuse type .
Lymphomas require immunophenotypic evaluation (immunohistochemistry and/or flow cytometry) to confirm the diagnosis . While there is tumor individuality, the neopla stic cells usually show a B cell phenotype (CDI9, CD20, CD22, CD79a) with coexpression of CDlO and CD43 ; they also express bcl-2 and bcl-6 and demonstrate light-chain (kappa or lambda) restriction. Approximately 85% of patients with follicular lymphoma have a t(14;18) 
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translocation in which the bcl-2 oncogene is transloc ated from chromosome 18 to the immunoglobulin heavy-chain locus on chromosome 14.Thi s result s in overexpression of bcl-2 , which confers a survival advantage to the malignant B cells by preventing apoptosis. There is a complex grading system for follicular lymphoma that is based on the proportion of centroblasts in 10 repre sentative neoplastic follicles :
• Grade I: ::;5 centroblasts per high-power field (HPF) • Grade 2: 6 to 15 centroblasts/HPF • Grade 3:~16 centroblasts/HPF. Grade I and grade 2 follicular lymphom as, which account for 80% of all cases, are indolent and incurab le, whereas grade 3 neopla sms , while more aggressive, are potentially curable. Tran sforma tion to a high-grade lymphoma occurs in 25 to 35% of patients . The treatment of choice is chemotherapy, which usually includes cyc lophosphamide, vincristine, and predni sone . There is potential for a better overall response when these agents are combined with monoclonal antibody therapy (e.g., rituximab). 
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